These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37533009)

  • 1. Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure.
    Packer M
    Cardiovasc Diabetol; 2023 Aug; 22(1):197. PubMed ID: 37533009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
    Packer M; Butler J
    Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Packer M; Wilcox CS; Testani JM
    Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
    Martens P; Dauw J; Verbrugge FH; Nijst P; Meekers E; Augusto SN; Ter Maaten JM; Damman K; Mebazaa A; Filippatos G; Ruschitzka F; Tang WHW; Dupont M; Mullens W
    Circulation; 2023 Jan; 147(3):201-211. PubMed ID: 36335479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
    Bjornstad P; Greasley PJ; Wheeler DC; Chertow GM; Langkilde AM; Heerspink HJL; Van Raalte DH
    J Card Fail; 2021 Dec; 27(12):1447-1455. PubMed ID: 34289398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
    Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
    Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
    Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
    Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.
    Tang J; Ye L; Yan Q; Zhang X; Wang L
    Front Pharmacol; 2022; 13():800490. PubMed ID: 35281930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
    J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
    Mullens W; Dauw J; Martens P; Verbrugge FH; Nijst P; Meekers E; Tartaglia K; Chenot F; Moubayed S; Dierckx R; Blouard P; Troisfontaines P; Derthoo D; Smolders W; Bruckers L; Droogne W; Ter Maaten JM; Damman K; Lassus J; Mebazaa A; Filippatos G; Ruschitzka F; Dupont M;
    N Engl J Med; 2022 Sep; 387(13):1185-1195. PubMed ID: 36027559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
    Hallow KM; Helmlinger G; Greasley PJ; McMurray JJV; Boulton DW
    Diabetes Obes Metab; 2018 Mar; 20(3):479-487. PubMed ID: 29024278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natriuretic Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload.
    Verbrugge FH; Martens P; Dauw J; Nijst P; Meekers E; Augusto SN; Ter Maaten JM; Damman K; Filippatos G; Lassus J; Mebazaa A; Ruschitzka F; Dupont M; Mullens W
    J Am Coll Cardiol; 2023 May; 81(20):2013-2024. PubMed ID: 37197845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload.
    Verbrugge FH; Dupont M; Bertrand PB; Nijst P; Penders J; Dens J; Verhaert D; Vandervoort P; Tang WH; Mullens W
    Acta Cardiol; 2015 Jun; 70(3):265-73. PubMed ID: 26226699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study.
    Dauw J; Charaya K; Lelonek M; Zegri-Reiriz I; Nasr S; Paredes-Paucar CP; Borbély A; Erdal F; Benkouar R; Cobo-Marcos M; Barge-Caballero G; George V; Zara C; Ross NT; Barker D; Lekhakul A; Frea S; Ghazi AM; Knappe D; Doghmi N; Klincheva M; Fialho I; Bovolo V; Findeisen H; Alhaddad IA; Galluzzo A; de la Espriella R; Tabbalat R; Miró Ò; Singh JS; Nijst P; Dupont M; Martens P; Mullens W
    Circ Heart Fail; 2024 Jan; 17(1):e011105. PubMed ID: 38179728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.